The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder

Table 4 The effect of Matrix Model treatment, MPH and matrix-methylphenidate on clinical parameters in METH users ¹

Group Variable	Matrix (n = 20)	Methylphenidate (n = 22)	Matrix combination with methylphenidate (n = 21)	Control (n = 22)	P-value^*	Effect size
DDQ² Baseline	53.4 ± 6.4	53.9 ± 4.8	54.9 ± 4.5	55.9 ± 4.5	< 0.001	0.387
End-of-trial	53.7 ± 5.7^a	51.2 ± 4.0	49.4 ± 5.5	56.4 ± 3.7^b	< 0.001	0.387
P-value^**	0.701	< 0.001	< 0.001	0.291
LDQ³ Baseline	21.2 ± 2.8	20.6 ± 2.6	22.3 ± 2.9	20.8 ± 2.8	< 0.001	0.226
End-of-trial	21.9 ± 2.9^a	19.5 ± 2.3	19.3 ± 1.4	20.2 ± 1.6	< 0.001	0.226
P-value^**	0.410	0.004	< 0.001	0.304
GHQ⁴ Baseline	31.4 ± 4.9	28.2 ± 6.6	30.9 ± 4.8	31.4 ± 5.3	0.001	0.178
End-of-trial	30.3 ± 4.2	27.6 ± 5.2	27.0 ± 5.0^c	30.6 ± 5.5	0.001	0.178
P-value^**	0.096	0.480	< 0.001	0.195

¹ Data are mean ± SDs
² DDQ: Desire for Drug Questionnaire
³ LDQ: Leeds Dependence Questionnaire
⁴ GHQ: General Health Questionnaire
a: Significant difference between Matrix with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
b: Significant difference between Control with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
c: Significant difference between Matrix combination with methylphenidate with other groups (Bonferroni test)
* ANCOVA test/ ** Paired t-test

ISSN: 1747-597X